Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRD | O14764 | 4/20 | 0.46 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.46 |
| ▸ | GABRB1 | P18505 | 4/20 | 0.46 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.46 |
| ▸ | GABRA3 | P34903 | 4/20 | 0.46 |
| ▸ | GABRA2 | P47869 | 4/20 | 0.46 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.46 |
| ▸ | GABRA4 | P48169 | 4/20 | 0.46 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30014379 | 0.94 | GABRD (0.51) | GABRDGABRA1GABRB1GABRA5GABRA3 | |
| SCHEMBL25596266 | 0.94 | GABRD (0.51) | GABRDGABRA1GABRB1GABRA5GABRA3 | |
| Hydrochloric Acid SCHEMBL30864123 | 0.93 | GABRD (0.50) | GABRDGABRA1GABRB1GABRA5GABRA3 | |
| Trifluoroacetic Acid SCHEMBL30392371 | 0.92 | PKM (0.44) | DDR1 | |
| Trifluoroacetic Acid SCHEMBL30392394 | 0.91 | DDR1 (0.40) | DDR1USP2NAMPTCYP2D6MAPK1 | |
| SCHEMBL30267288 | 0.86 | GABRD (0.41) | GABRDGABRA1GABRB1GABRA5GABRA3 | |
| Trifluoroacetic Acid SCHEMBL31161289 | 0.85 | LRRK2 (0.43) | — | |
| SCHEMBL26100334 | 0.85 | NAMPT (0.41) | GABRDGABRA1GABRB1GABRA5GABRA3 | |
| SCHEMBL30014819 | 0.85 | HPGD (0.43) | GABRDGABRA1GABRB1GABRA5GABRA3 | |
| SCHEMBL30392608 | 0.85 | HPGD (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125400-A1 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| WO-2024220937-A2 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2024-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125400-A1 | TYK2 DEGRADERS AND USES THEREOF | TYK2, CSNK2A1, CSNK2A2 | GABRD 1698/4885GABRA1 1230/4885GABRB1 1627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.